Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes

Haematologica

Volumn 91, Issue 12, 2006, Pages 1596-1604

  Germing, Ulrich ^a   Strupp, Corinna ^a   Kuendgen, Andrea ^a   Isa, Shadi ^a   Knipp, Sabine ^a   Hildebrandt, Barbara ^b   Giagounidis, Aristoteles ^c   Aul, Carlo ^c   Gattermann, Norbert ^a   Haas, Rainer ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Institute for Human Genetics   (United Kingdom)

^c ST JOHANNES HOSPITAL   (Germany)

Author keywords

Myelodysplastic syndromes; Prognosis; WHO classification

Indexed keywords

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CLINICAL DECISION MAKING; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; GERMANY; HEALTH CARE; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; PRACTICE GUIDELINE; PROGNOSIS; SCORING SYSTEM; SIDEROBLASTIC ANEMIA; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; SURVIVAL RATE; WORLD HEALTH ORGANIZATION;

EID: 33845935489     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
2. Harris NL, Jaffe ES, Diebold J, Muller-Hermelink HK, Vardiman J, Lister TA, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. J Clin Oncol 1999;17:3835-49.
3. Bennett JM. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 2000;72:131-3.
4. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. WHO Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon; 2001.
5. Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000;24:983-92.
6. Lorand-Metze I, Pinheiro MP, Ribeiro E, de Paula EV, Metze K. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications. Leuk Res 2004;28:587-94.
7. Lee JH, Lee JH, Shin YR, Lee JS, Kim WK, Chi HS, et al. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia 2003;17:305-13.
8. Nosslinger T, Reisner R, Koller E, Gruner H, Tuchler H, Nowotny H, et al. Myelodysplastic syndromes, from Frencn-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood 2001;98:2935-41.
9. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594-603
10. Mitelman F, ed. ISCN: an International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995.
11. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
13. Cox DR. Regression models and life-tables. J R Stat Soc 1972;34:187-220.
14. Aul C, Gattermann N, Heyll A, U, Derigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992;6:52-9.
15. Germing U, Hildebrandt B, Pfeilstocker M, Nosslinger T, Valent P, Fonatsch C, et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 2005;19:2223-31.
16. Greenberg P, Anderson J, de Witte T, Estey E, Fenaux P, Gupta P, et al. Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. J Clin Oncol 2000;18:3447-52.
17. Bennett JM, Brunning RD, Vardiman JW. Myelodysplastic syndromes: from French-American-British to World Health Organization: a commentary. Blood 2002;99:3074-5.
18. Strupp C, Gattermann N, Giagounidis A, Aul C, Hildebrandt B, Haas R, et al. Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals. Leuk Res 2003;27:397-404.
19. Gattermann N, Aul C, Schneider W. Two types of acquired idiopathic sideroblastic anaemia (AISA). Br J Haematol 1990;74:45-52.
20. Germing U, Gattermann N, Aivado M, Hildebrandt B, Aul C. Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction. Br J Haematol 2000;108:724-8.
21. Gattermann U. Refractory anemia with excess of blasts in transformation: a dying category? Leuk Res 2001; 25:1095-6.
22. Rosati S, Mick R, Xu F, Stonys E, Le Beau MM, Larson R, et al. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome. Leukemia 1996;10:20-6.
23. Balduini CL, Guarnone R, Pecci A, Centenara E, Ascari E. Multilineage dysplasia without increased blasts identifies a poor prognosis subset of myelodysplastic syndromes. Leukemia 1998;12:1655-6.
24. Garand R, Gardais J, Bizet M, Bremond JL, Accard F, Callat MP, et al. Heterogeneity of acquired idiopathic sideroblastic anaemia (AISA). Leuk Res 1992;16:463-8.
25. Matsuda A, Jinnai I, Yagasaki F, Kusumoto S, Minamihisamatsu M, Honda S, et al. Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia. Leukemia 1998;12:482-5.
26. Xiao Z, Yu M, Liu S. Application of Who classification in Chinese patients with primary myelodysplastic syndromes. Leuk Res 2005 (Suppl 1);29:S31-S32.
27. Cobol F, Sierra E, Rozman M, et al. Reclassification of FAB chronic myelomonocytic leukemia (CMML) according to the World Health Organization (WHO) criteria: An analysis of 41 patients from a single institution. Leuk Res 2005;Suppl 129:S36.
28. Matsuda A, U, Jinnai I. Prognostic factors in refractory anemia according to the French-American-British classification. Leuk Res 2005;Suppl 129:S27.
29. Breccia M, Carmosino I, Biondo F, Mancini M, Russo E, Latagliata R, et al. Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodyplastic syndromes. Leuk Res 2006;30:178-82.
30. Rong A, Gattermann N, U, Aul C, Aivado M. RAS Mutations are rare in acquired idiopathic sideroblastic anemia (AISA) and apparently absent in pure sideroblastic anemia (PSA). Onkologie 2000;23 Suppl 7:A181
31. Cermak J, Vitek A, Michalova K. Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation. Leuk Res 2004;28:543-4.
32. Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellstrom-Lindberg E. The WHO classification of MDS does make a difference. Blood 2004;103:3265-70.
33. Stadler M, U, Kliche KO, Josten KM, Kuse R, Hofmann WK, Sk, et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004;18:460-5.
34. Aivado M, Rong A, Stadler M, Giagounidis A, Strupp C, Novotny J, et al. avourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X chromosome inactivation in bone marrow cells. Eur J Haematol 2002;68:210-6
35. Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B, Steidl C, et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol 2005;84 Suppl 13:61-6.
36. Cermak J, Vitek A, Michalova K. Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation. Leuk Res 2004;28:551-7.
37. Malcovati L, Della Porta MG, Lunghi M, Pascutto C, Vanelli L, Travaglino E, et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia 2005;19:776-83.
38. + cells from normal and myelodysplastic bone marrow. Blood 2002;100:3553-60.
39. + cells from patients with myelodysplastic syndrome. Blood 2002;100:166A.
40. Chen Z, Qian J, Wang W. Gene expression profiling of the bone marrow mononucle-ar cells from patients with myelodysplastic syndrome. Leuk Res 2005;29 Suppl 1:S7-S8.
41. Aivado M, Spentzos D, Alterovitz G, Meng XY, Grail F, Giagounidis AAN, et al. Serum protein profiling with mass spectrometry for the diagnosis of myelodysplastic syndromes. Blood 2362;104:649A-649A.
42. Giagounidis AA, U, Haase S, et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 2004;18:113-99.
43. Giagounidis AA, Germing U, Strupp C, Hildebrandt B, Heinsch M, Aul C. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann Hematol 2005;84:569-71
44. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549-57.
45. Marisavljevic D, Rolovic Z, Cemerikic V, Boskovic D, Colovic M. Myelofibrosis in primary myelodysplastic syndromes: clinical and biological significance. Med Oncol 2004;21:325-31.
46. Steensma DP, Hanson CA, Letendre L, Tefferi A. Myelodysplasia with fibrosis: a distinct entity? Leuk Res 2001;25:829-38.
47. Knipp S, Aul C, Giagounidis AAN, et al. Presence of peripheral blasts in RA and RARS predicts an unfavourable outcome. Leuk Res 2005;Suppl 129:S26.
48. Knipp S, Reinecke P, Braunstein S, et al. Prognostic impact of bone marrow cellularity in myelodysplastic syndromes on overall survival. Leuk Res 2005;Suppl 129:526.
49. Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM. Hypocellular myelodysplastic syndromes (MDS): new proposals. Br J Haematol 1995;91:612-7.
50. Barrett J. Myelodysplastic syndrome and aplastic anemia-diagnostic and conceptual uncertainties. Leuk Res 2000;24:595-6.
51. Germing U, Gattermann N, Minning H, Heyll A, Aul C. Problems in the classificatio of CMML-dysplastic versus proliferative type. Leuk Res 1998;22:871-8.
52. Neuwirtova R, Mocikova K, Musilova J, Jelinek J, Havlicek F, Michalova K, et al. Mixed myelodysplastic and myeloproliferative syndromes. Leuk Res 1996;20:717-26.
53. Knipp S, Strupp C, Bernhardt A, et al. RA and RARS with thrombocytosis: Mixed myelodysplastic/myeloproliferative disorder? Leuk Res 2005;Suppl 129:S35
54. Schmitt-Graeff A, Thiele J, Zuk I, Kvasnicka HM. Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity. Haematologica 2002;87:392-9.